Woman Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To determine the benefit of exemestane plus enzalutamide versus exemestane plus placebo as assessed by progression free survival (PFS) in patients with advanced breast cancer that is estrogen and/or progesterone receptor positive and human epidermal growth factor receptor 2 (HER2) normal and in the subset of patients with a genomic signature of differential gene expression based on RNA sequencing (Dx).
Inclusion criteria
- Breast Cancer